Cardialen CESS V5

  • Research type

    Research Study

  • Full title

    Measurement of Low-energy Stimulation in Patients with Atrial Fibrillation

  • IRAS ID

    164828

  • Contact name

    Nicholas Peters

  • Contact email

    n.peters@imperial.ac.uk

  • Sponsor organisation

    Cardialen Inc

  • Clinicaltrials.gov Identifier

    NCT02257112

  • Duration of Study in the UK

    0 years, 6 months, 2 days

  • Research summary

    The primary objective of the study is to evaluate the safety and performance of patients with atrial fibrillation when receiving treatment with the CESS device.

    Atrial Fibrillation is a common problem which affects the rate of a person’s heartbeat. This can be that the heartbeat is too fast, too slow or with an irregular rhythm.

    Cardialen External Stimulation System (CESS) is a device that uses a number of Therapies to restore atrial fibrillation back to a normal rhythm. Restoring the heart rhythm eases the patients’ symptoms and thereby is aimed at improving their quality of life.

    CESS will deliver low-energy atrial stimulation therapy through a multi-stage process, this is delivered with Medtronic Sprint Quattro Defibrillation Leads which are placed into the heart.

    This study involves the testing of the CESS device in patients with atrial fibrillation prior to their normal scheduled catheter insertion procedure (a procedure in which an electric current is used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). The low-voltage electric current enters the body through metal paddles or patches applied to the chest. This is the method typically used to treat atrial fibrillation.

    45 subjects who show a current need for this type of treatment due to atrial fibrillation will receive the study therapy. This will include up to 5 sites worldwide, currently we have one site set up in France and one in the USA. Approvals are being sought for the study to be conducted at one site in Poland and another in the UK, each site will enrol and treat up to 15 patients.

    The study therapy will be delivered with increasing voltages and timing sequence changes until atrial fibrillation is successfully finished. The study therapy may be completed multiple times within 60 minutes prior to the scheduled standard therapy.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    14/LO/2143

  • Date of REC Opinion

    28 Jan 2015

  • REC opinion

    Further Information Favourable Opinion